APA (7th ed.) Citation

S, M., P, S., T, Y., R, K., SK, S., K, Y., . . . AA, D. (2026). Topical administration of in situ gelling formulation containing myricetin-polycarboxylate nanoparticles inhibits murine genital herpes infection. International journal of pharmaceutics, 695, 126672. https://doi.org/10.1016/j.ijpharm.2026.126672

Chicago Style (17th ed.) Citation

S, Mallick, et al. "Topical Administration of in Situ Gelling Formulation Containing Myricetin-polycarboxylate Nanoparticles Inhibits Murine Genital Herpes Infection." International Journal of Pharmaceutics 695 (2026): 126672. https://doi.org/10.1016/j.ijpharm.2026.126672.

MLA (9th ed.) Citation

S, Mallick, et al. "Topical Administration of in Situ Gelling Formulation Containing Myricetin-polycarboxylate Nanoparticles Inhibits Murine Genital Herpes Infection." International Journal of Pharmaceutics, vol. 695, 2026, p. 126672, https://doi.org/10.1016/j.ijpharm.2026.126672.